Pharmagen, Inc.
Other OTCTotal Valuation
Pharmagen, Inc. carries a market capitalization of 5,171.00, placing it among publicly traded companies globally. Its enterprise value stands at 7.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5,171.00 |
| Enterprise Value | 7.03M |
Share Statistics
Pharmagen, Inc. currently has 504.45M shares outstanding.
| Shares Outstanding | 504.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.36, and the price-to-book ratio stands at -0.17.
| PE Ratio | N/A |
| PS Ratio | 0.36 |
| PB Ratio | -0.17 |
| P/TBV Ratio | -0.19 |
| P/FCF Ratio | -4.12 |
| P/OCF Ratio | -3.24 |
Enterprise Valuation
| EV / Sales | 1.59 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 2.67 |
Financial Position
Pharmagen, Inc. maintains a current ratio of 0.10, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -71.34, indicating conservative leverage, while an interest coverage ratio of -0.71 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.10 |
| Quick Ratio | 0.07 |
| Debt / Equity | -71.34 |
| Debt / EBITDA | -2.68 |
| Interest Coverage | -0.71 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -246.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 9.45 |
Income Statement
Over the trailing twelve months, Pharmagen, Inc. generated 4.41M in revenue and converted that into -5.87M in net income, yielding earnings per share of -0.01. EBITDA reached -2.14M, while operating income came in at -2.24M.
| Revenue | 4.41M |
| Gross Profit | 2.75M |
| Operating Income | -2.24M |
| Pretax Income | -2.21M |
| Net Income | -5.87M |
| EBITDA | -2.14M |
| EBIT | -2.24M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Pharmagen, Inc. holds 264,673.00 in cash and equivalents against 5.73M in total debt, resulting in a net debt position of 5.15M. Total book value stands at -9.35M, with working capital of -7.46M providing operational flexibility.
| Cash & Cash Equivalents | 264,673.00 |
| Total Debt | 5.73M |
| Net Debt | 5.15M |
| Equity (Book Value) | -9.35M |
| Book Value Per Share | -0.02 |
| Working Capital | -7.46M |
Cash Flow
Pharmagen, Inc. produced -483,093.00 in operating cash flow over the past twelve months. After subtracting -102,607.00 in capital expenditures, free cash flow totaled -585,700.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -483,093.00 |
| Capital Expenditures | -102,607.00 |
| Free Cash Flow | -585,700.00 |
| FCF Per Share | 0.00 |
Margins
Pharmagen, Inc. operates with a gross margin of 62.35, reflecting its pricing power and cost economics. The operating margin of -50.83 and net profit margin of -133.10 provide insight into operational efficiency.
| Gross Margin | 62.35 |
| Operating Margin | -50.83 |
| Pretax Margin | -50.18 |
| Profit Margin | -133.10 |
| EBITDA Margin | -48.43 |
Dividends & Yields
The company's payout ratio of 1.67 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 1.67 |
| Shareholder Yield | -12.99 |
| FCF Yield | -24.29 |
Scores
Pharmagen, Inc. posts an Altman Z-Score of -20.32, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.32 |